Literature DB >> 24075647

Role of the intestinal microbiome in liver disease.

Jorge Henao-Mejia1, Eran Elinav, Christoph A Thaiss, Paula Licona-Limon, Richard A Flavell.   

Abstract

The liver integrates metabolic outcomes with nutrient intake while preventing harmful signals derived from the gut to spread throughout the body. Direct blood influx from the gastrointestinal tract through the portal vein makes the liver a critical firewall equipped with a broad array of immune cells and innate immune receptors that recognize microbial-derived products, microorganisms, toxins and food antigens that have breached the intestinal barrier. An overwhelming amount of evidence obtained in the last decade indicates that the intestinal microbiota is a key component of a wide variety of physiological processes, and alterations in the delicate balance that represents the intestinal bacterial communities are now considered important determinants of metabolic syndrome and immunopathologies. Moreover, it is now evident that the interaction between the innate immune system and the intestinal microbiota during obesity or autoimmunity promotes chronic liver disease progression and therefore it might lead to novel and individualized therapeutic approaches. In this review, we discuss a growing body of evidence that highlights the central relationship between the immune system, the microbiome, and chronic liver disease initiation and progression.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Innate immune system; Microbiota; Non-alcoholic fatty liver disease; Primary biliary cirrhosis

Mesh:

Year:  2013        PMID: 24075647     DOI: 10.1016/j.jaut.2013.07.001

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  53 in total

1.  The challenge of treating orphan disease.

Authors:  Carlos Dias; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease.

Authors:  Janka Babickova; Roman Gardlik
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 3.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

Review 4.  Gut microbiota modulate the immune effect against hepatitis B virus infection.

Authors:  D Xu; Y Huang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-14       Impact factor: 3.267

5.  Beneficial effects of LRP6-CRISPR on prevention of alcohol-related liver injury surpassed fecal microbiota transplant in a rat model.

Authors:  Linghua Yu; Linlin Wang; Huixing Yi; Xiaojun Wu
Journal:  Gut Microbes       Date:  2020-03-13

6.  Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice.

Authors:  Magdalena Mazagova; Lirui Wang; Andrew T Anfora; Max Wissmueller; Scott A Lesley; Yukiko Miyamoto; Lars Eckmann; Suraj Dhungana; Wimal Pathmasiri; Susan Sumner; Caroline Westwater; David A Brenner; Bernd Schnabl
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

Review 7.  Inflammasomes and the microbiota--partners in the preservation of mucosal homeostasis.

Authors:  Maayan Levy; Christoph A Thaiss; Meirav N Katz; Jotham Suez; Eran Elinav
Journal:  Semin Immunopathol       Date:  2014-10-15       Impact factor: 9.623

Review 8.  Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.

Authors:  Veerle Bieghs; Christian Trautwein
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

Review 9.  Sex-related factors in autoimmune liver diseases.

Authors:  Dorothee Schwinge; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623

Review 10.  Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma.

Authors:  Antonio Galvao Neto; April Whitaker; Zhiheng Pei
Journal:  Semin Oncol       Date:  2015-09-07       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.